Teva Pharmaceutical Industries Ltd (TEVA) stock
TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30119% above fair value
$43.65+0.41 (+0.95%)
Close on Nov 12, 2026Market cap $50.87BP/E 72.8Yield –
Teva Pharmaceutical Industries r&d expenses
Research and development expenses are spending on new products and technology.
Teva Pharmaceutical Industries's R&D Expenses for the twelve months ending Jun 30, 2026 was $1.72B, up 75.4% year over year. For fiscal 2025 it was $1.01B, up 1.5% from the year before. Over ten years it grew 40.0% a year on average. The highest annual figure on record is $1.21B in fiscal 2018.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.01B | +1.5% |
| FY2024 | Dec 31, 2024 | $998.00M | +4.7% |
| FY2023 | Dec 31, 2023 | $953.00M | +13.7% |
| FY2022 | Dec 31, 2022 | $838.00M | -13.3% |
| FY2021 | Dec 31, 2021 | $967.00M | -3.0% |
| FY2020 | Dec 31, 2020 | $997.00M | -1.3% |
| FY2019 | Dec 31, 2019 | $1.01B | -16.7% |
| FY2018 | Dec 31, 2018 | $1.21B | +593.1% |
| FY2017 | Dec 31, 2017 | $175.00M | -58.5% |
| FY2016 | Dec 31, 2016 | $422.00M | +1105.7% |
| FY2015 | Dec 31, 2015 | $35.00M | – |
| FY2014 | Dec 31, 2014 | $0 | -100.0% |
| FY2013 | Dec 31, 2013 | $5.00M | -93.2% |
| FY2012 | Dec 31, 2012 | $73.00M | +386.7% |
| FY2011 | Dec 31, 2011 | $15.00M | -98.4% |
| FY2010 | Dec 31, 2010 | $951.00M | +15.3% |
| FY2009 | Dec 31, 2009 | $825.00M | +5.0% |
| FY2008 | Dec 31, 2008 | $786.00M | +35.3% |
| FY2007 | Dec 31, 2007 | $581.00M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $970.00M | +297.5% |
| Q1 FY2026 | Mar 31, 2026 | $222.00M | -10.1% |
| Q4 FY2025 | Dec 31, 2025 | $267.00M | +8.1% |
| Q3 FY2025 | Sep 30, 2025 | $256.00M | +6.7% |
| Q2 FY2025 | Jun 30, 2025 | $244.00M | -9.3% |
| Q1 FY2025 | Mar 31, 2025 | $247.00M | +2.1% |
| Q4 FY2024 | Dec 31, 2024 | $247.00M | +8.8% |
| Q3 FY2024 | Sep 30, 2024 | $240.00M | -5.1% |
| Q2 FY2024 | Jun 30, 2024 | $269.00M | +12.1% |
| Q1 FY2024 | Mar 31, 2024 | $242.00M | +3.4% |
| Q4 FY2023 | Dec 31, 2023 | $227.00M | +8.1% |
| Q3 FY2023 | Sep 30, 2023 | $253.00M | +44.6% |
| Q2 FY2023 | Jun 30, 2023 | $240.00M | +5.3% |
| Q1 FY2023 | Mar 31, 2023 | $234.00M | +4.0% |
| Q4 FY2022 | Dec 31, 2022 | $210.00M | -13.9% |
| Q3 FY2022 | Sep 30, 2022 | $175.00M | -21.2% |
| Q2 FY2022 | Jun 30, 2022 | $228.00M | -8.1% |
| Q1 FY2022 | Mar 31, 2022 | $225.00M | -11.4% |
| Q4 FY2021 | Dec 31, 2021 | $244.00M | -16.7% |
| Q3 FY2021 | Sep 30, 2021 | $222.00M | -14.0% |
| Q2 FY2021 | Jun 30, 2021 | $248.00M | +10.2% |
| Q1 FY2021 | Mar 31, 2021 | $254.00M | +14.9% |
| Q4 FY2020 | Dec 31, 2020 | $293.00M | +26.3% |
| Q3 FY2020 | Sep 30, 2020 | $258.00M | +7.5% |
| Q2 FY2020 | Jun 30, 2020 | $225.00M | -18.5% |
| Q1 FY2020 | Mar 31, 2020 | $221.00M | -15.3% |
| Q4 FY2019 | Dec 31, 2019 | $232.00M | -80.0% |
| Q3 FY2019 | Sep 30, 2019 | $240.00M | -22.8% |
| Q2 FY2019 | Jun 30, 2019 | $276.00M | -4.8% |
| Q1 FY2019 | Mar 31, 2019 | $261.00M | +383.3% |
| Q4 FY2018 | Dec 31, 2018 | $1.16B | – |
| Q3 FY2018 | Sep 30, 2018 | $311.00M | -41.4% |
| Q2 FY2018 | Jun 30, 2018 | $290.00M | -38.2% |
| Q1 FY2018 | Mar 31, 2018 | $54.00M | -87.5% |
| Q4 FY2017 | Dec 31, 2017 | $0 | -100.0% |
| Q3 FY2017 | Sep 30, 2017 | $531.00M | -19.9% |
| Q2 FY2017 | Jun 30, 2017 | $469.00M | – |
| Q1 FY2017 | Mar 31, 2017 | $432.00M | – |
| Q4 FY2016 | Dec 31, 2016 | $160.00M | – |
| Q3 FY2016 | Sep 30, 2016 | $663.00M | – |
See a number that looks wrong?